Clinical trial costs
By Dr. Matthew Watson
Based on a survey* of 21 drug makers, 12 biotechs, nine device makers and 23 contract research organizations, PharmaLot has recently published the following metrics for current clinical trial costs (see full article here)
Average per-patient trial costs across all therapeutic areas:
Phase I: $21,883
Phase II: $36,070
Phase IIIa: $47,523
Phase IIIb: $47,095
Phase IV: $17,042
Average cost per patient for a cardiovascular trial:
Phase II: $33,700
Phase IIIa: $21,750
Phase IIIb: $6,830
In oncology, the average per patient trial cost:
Phase II: $73,303
Phase IIIa: $57,207
Phase IIIb: $65,900
For central nervous system disorders:
Phase II: $28,197
Phase IIIa: $33,768
Phase IIIb: $41,824
For diabetes:
Phase II: $ 8,854
Phase IIIa: $12,667
Phase IIIb: $10,700
Anyone have any thoughts or data as to how this compares to cell therapy trials?
--Lee
*survey conducted by Cutting Edge Information.
Related Post
- Commercialization of Regenerative Medicine: Learning from Spin-Outs - April 28th, 2013
- 2013 Annual Regenerative Medicine Industry Report - April 21st, 2013
- Cell Therapy Blog welcomes 2013 - January 6th, 2013
- The Accuracy of Adipose Stem Cell Doses - December 23rd, 2012
- A proposed 6-step platform for the cell therapy industry to consider in combating non-compliant cell therapy treatments - December 16th, 2012
- The ROI on pant-wearing and other social media tips - December 16th, 2012
- Six steps to fighting non-compliant cell therapy treatments. --- The stuff of grey shades, spades, ivory towers and (ahem) balls. - December 2nd, 2012
- Cell Therapy Industry Group Welcomes its 4,000th member - November 11th, 2012
- GEN's "Cellular Therapy Wave Finally Cresting". An overview and data set. - November 4th, 2012
- CIRM addresses some tough questions. Is it all just glass towers and basic research? - October 21st, 2012
- Cell therapy portfolio outperforms major indices year-to-date - October 14th, 2012
- The cost of clinical trial data bias/loss, FDA's new job and the need for bold leadership. - September 30th, 2012
- Anticipated short-term cell therapy industry clinical milestones - September 30th, 2012
- Two lessons I learned this week. - September 16th, 2012
- Are some cell counts too good to be true? Why some companies' product data may mislead. - September 2nd, 2012
- Is the cell therapy sector outperforming the major indices? - August 12th, 2012
- FDA 1. RSI 0. Regenerative Sciences (Regenexx) vs FDA (2012) - July 29th, 2012
- Bioreactor Design and Bioprocess Controls for Industrialized Cell Processing - June 17th, 2012
- Industry-sponsored cardiovascular cell therapies. Some metrics. - May 27th, 2012
- Cell-based Cancer Immunotherapies. Some metrics.. - May 20th, 2012
- Another > $100M month for companies in the cell therapy space - May 6th, 2012
- Predicting the Success of the Late-Stage Cell-Based Cancer Immunotherapy Pipeline? - March 11th, 2012
- 2011 EMA Committee for Advanced Therapies (CAT) classification record. What can be learned? - January 1st, 2012
- Inactive and recently failed or terminated phase III or II/III cell therapy trials - December 18th, 2011
- Recently approved cell therapy products - December 18th, 2011
- Active phase III or II/III cell therapy trials - December 11th, 2011
- Sabrina Cohen Foundation Thanks Stem Cell Researchers - November 27th, 2011
- Commercializing Cell-based Regenerative Medicines - November 13th, 2011
- Cell Therapy & Regenerative Medicine Domains Available - September 25th, 2011
- Commercial-stage Cell Therapy Companies and Products - September 18th, 2011
- Potential far-reaching implications of the ongoing fight over point-of-care autologous cell therapy - September 18th, 2011
- Good Data? $100. Good Product Development? $100. Good Commercialization Strategy? Priceless. - August 14th, 2011
- Cell Therapy's Got Talent Technology Showcase - A Call for Cell Therapy Manufacturing Technology Presentations - July 10th, 2011
- In vivo cell trafficking just took a leap forward - July 3rd, 2011
- Cell Therapies: Commercializing a New Class of Biopharmaceuticals - February 12th, 2011
- The LinkedIn Cell Therapy Industry Group - 1,000 members strong - January 15th, 2011
- Careers in cell therapy & regenerative medicine - October 11th, 2010
- FDA files injunction again Regenerative Sciences citing Regenexx violates regulations - August 12th, 2010
- The changing face of PR and why it matters to regenmed - June 12th, 2010
- Biotech tax credit appears perfectly designed for cell therapy companies to recoup research dollars spent in 2009-10 - May 22nd, 2010
- Google to Invest in Regenerative Medicine - May 5th, 2010
- Latest Cell Therapy Approval by FDA. Dendreon's Provenge. - April 30th, 2010
- Stem cells for a Webby! - April 28th, 2010
July 31st, 2011
This author published 5912 posts in this site.Share
Comments are closed.
Personalized Gene Medicine
| Mesenchymal Stem Cells
| Stem Cell Treatment for Multiple Sclerosis
| Stem Cell Treatments
| Board Certified Stem Cell Doctors
| Stem Cell Medicine
| Personalized Stem Cells Therapy
| Stem Cell Therapy TV
| Individual Stem Cell Therapy
| Stem Cell Therapy Updates
| MD Supervised Stem Cell Therapy
| IPS Stem Cell Org
| IPS Stem Cell Net
| Genetic Medicine
| Gene Medicine
| Longevity Medicine
| Immortality Medicine
| Nano Medicine
| Gene Therapy MD
| Individual Gene Therapy
| Affordable Stem Cell Therapy
| Affordable Stem Cells
| Stem Cells Research
| Stem Cell Breaking Research